» Articles » PMID: 1575454

Transplantation of Fetal Dopamine Neurons in Parkinson's Disease: One-year Clinical and Neurophysiological Observations in Two Patients with Putaminal Implants

Overview
Journal Ann Neurol
Specialty Neurology
Date 1992 Feb 1
PMID 1575454
Citations 55
Authors
Affiliations
Soon will be listed here.
Abstract

Ventral mesencephalic tissue from aborted human fetuses (age, 6-7 weeks' postconception) was implanted unilaterally into the putamen using stereotaxic surgery in 2 immunosuppressed patients (Patients 3 and 4 in our series) with advanced idiopathic Parkinson's disease. Tissue from 4 fetuses was grafted to each patient. Compared with our previous 2 patients, the following changes in the grafting procedure were introduced: the implantation instrument was thinner, more tissue was placed in the operated structure, and the time between abortion and grafting was shorter. There were no postoperative complications. Both patients showed a gradual and significant amelioration of parkinsonian symptoms (most marked in Patient 3) starting at 6 and 12 weeks after grafting, respectively, reaching maximum stability at approximately 4 to 5 months; patients remained relatively stable thereafter during the 1-year follow-up period. Clinical improvement was observed as a reduction of the time spent in the "off" phase and the number of daily "off" periods; a lessening of bradykinesia and rigidity during the "off" phase, mainly but not solely on the side contralateral to the graft; and a prolongation and change in the pattern of the effect of a single dose of L-dopa. Neurophysiological measurements revealed a more rapid performance of simple and complex arm and hand movements bilaterally, but primarily contralateral to the graft. The results indicate that patients with Parkinson's disease can show significant and sustained improvement of motor function after intrastriatal implantation of fetal dopamine-rich mesencephalic tissue. The accompanying paper by Sawle and colleagues describes the results of repeated positron emission tomography scans in these patients.

Citing Articles

Past, present, and future of cell replacement therapy for parkinson's disease: a novel emphasis on host immune responses.

Park T, Jeon J, Cha Y, Kim K Cell Res. 2024; 34(7):479-492.

PMID: 38777859 PMC: 11217403. DOI: 10.1038/s41422-024-00971-y.


Cell reprogramming therapy for Parkinson's disease.

Dong W, Liu S, Li S, Wang Z Neural Regen Res. 2024; 19(11):2444-2455.

PMID: 38526281 PMC: 11090434. DOI: 10.4103/1673-5374.390965.


Dopaminergic Cell Replacement for Parkinson's Disease: Addressing the Intracranial Delivery Hurdle.

Maheshwari S, Akram H, Bulstrode H, Kalia S, Morizane A, Takahashi J J Parkinsons Dis. 2024; 14(3):415-435.

PMID: 38457149 PMC: 11091588. DOI: 10.3233/JPD-230328.


Cell-therapy for Parkinson's disease: a systematic review and meta-analysis.

Wang F, Sun Z, Peng D, Gianchandani S, Le W, Boltze J J Transl Med. 2023; 21(1):601.

PMID: 37679754 PMC: 10483810. DOI: 10.1186/s12967-023-04484-x.


Human stem cell-derived neurons and neural circuitry therapeutics: Next frontier in spinal cord injury repair.

Paredes-Espinosa M, Paluh J Exp Biol Med (Maywood). 2022; 247(23):2142-2151.

PMID: 35974701 PMC: 9837306. DOI: 10.1177/15353702221114099.